课题基金 / 基金详情

Molecular Mechanisms Controlling NK Receptors

Molecular Mechanisms Controlling NK Receptors
控制 NK 受体的分子机制
批准号:
8224060
负责人:
Charles T. Lutz
金额:
$36.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-01 至 2013-08-31
关键词:
AbbreviationsAddressAffectAftercareAllelesAttentionAutoimmunityB-LymphocytesBerylliumBindingBioinformaticsCREB1 geneCancer PatientCatalogingCatalogsCellsChromatinCo-ImmunoprecipitationsCommunicable DiseasesComplementDNADNA MethylationDNA MethyltransferaseDNA Modification MethylasesDataDevelopmentDiseaseDistalDouble-Stranded RNADysmyelopoietic SyndromesEMSAElectrophoretic Mobility Shift AssayElementsEpigenetic ProcessFluorescenceFutureGene ExpressionGene Expression RegulationGenesGenetic TranscriptionGoalsHealthHistone DeacetylaseHistone Deacetylase InhibitorHistone H3HumanHuman Herpesvirus 4ImmunityImmunoglobulinsIn VitroIndividualInterleukin-15Interleukin-2InvestigationKiller CellsKnowledgeLeadLicensingLigandsLymphocyteLymphocyte FunctionLymphomaLysineMHC Class I GenesMaintenanceMalignant NeoplasmsMessenger RNAMethodsMethylationMicroRNAsMolecularMusNK Cell ActivationNatural ImmunityNatural Killer CellsNon-MalignantNucleotidesPatientsPatternPharmaceutical PreparationsPhysiologyProductionProteinsQuantitative Reverse Transcriptase PCRRNA Polymerase IIReagentReceptor GeneRegulationResearchResearch TechnicsRetroviridaeReverse Transcriptase Polymerase Chain ReactionRoleSerumSiteStem cellsT-LymphocyteT-Lymphocyte and Natural Killer CellTestingTimeTranscription Factor TFIIBTranscriptional RegulationTransfectionUntranslated RegionsVirusWorkadaptive immunityantibody-dependent cell cytotoxicitybasecancer cellcancer immunotherapycancer therapycell killingchemokinechromatin immunoprecipitationcytokinecytotoxiccytotoxicitydemethylationeffective therapyexpectationgene functionhistone modificationhuman diseasein vivoinnovationinsightkiller immunoglobulin-like receptornovelpromoterreceptorreceptor expressionreceptor functionresponsetranscription factor

项目摘要

项目成果

Charles T. Lutz的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Natural killer (NK) cells kill infected and malignant cells and direct subsequent adaptive immunity. NK cells distinguish normal from aberrant cells largely via killer cell immunoglobulin-like receptors (KIR). Despite high homology between KIR genes, individual NK cells express distinct numbers and combinations of clonally-restricted KIR (crKIR) genes. In contrast to crKIR, KIR2DL4 is expressed by all NK cells, preceding crKIR expression during NK development. The long-range goal is to use NK cells as effective treatments of cancer and infectious diseases. As the next logical step toward that goal, the current objectives are to further characterize KIR expression control in normal physiology and during epigenetic therapy of lymphoma and myelodysplastic syndrome. The rationale for the proposed research is that once KIR gene regulation is better understood, then KIR expression can be manipulated to make effective NK cells reagents in immunotherapy of cancer and infectious diseases. In this proposal, 2DL4 and crKIR promoters will be investigated, with special attention to mechanisms that overcome DNA methylation and repressive chromatin. Because so little is known about how lymphocyte-specific gene expression is influenced by cancer and by epigenetic therapy, we will study how DNA methylation and histone deacetylase inhibitor drugs affect KIR promoter methylation, KIR expression, and NK cell activation in myelodysplastic syndrome and lymphoma patients. This work may explain why NK function is poor in cancer patients and might suggest strategies for boosting immunity in these patients. We will catalog NK cell microRNA expression and their target mRNAs and we will investigate the microRNA mechanisms that regulate "dangerous" cytotoxic NK cells and "unlicensed" inhibitory receptor- negative NK cells. This will provide the basic information needed for future studies on control of NK developmental decisions in health and disease. This study will 1) develop a clear understanding of the multiple layers of regulation that control the initiation and maintenance of KIR expression; 2) establish for the first time how epigenetic therapy affects nonmalignant human lymphocyte gene expression and function in vivo; and 3) reveal NK-specific microRNA patterns and elucidate how they control mRNA targets to regulate NK development and set NK cell activation thresholds. These results will be highly significant, because they will be essential for understanding how NK cells distinguish normal from aberrant cells. Such an understanding will suggest new ways to manipulate NK cells in the therapy of cancer and infectious diseases. PUBLIC HEALTH RELEVANCE: Natural killer (NK) cells kill infected and malignant cells and direct subsequent adaptive immunity. The long-range goal is to use NK cells as effective treatments of cancer and infectious diseases. As the next logical step toward that goal, the current objectives are to further characterize NK gene expression control in normal physiology and in cancers and pre-cancers, such as lymphoma and myelodysplastic syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Muscle, Fat and NK Lymphocytes in Aging
  • 批准号:
    8517537
  • 项目类别:
  • 资助金额:
    $17.54万
  • 财政年份:
    2012
  • 负责人:
    Charles T. Lutz
  • 依托单位:
Muscle, Fat and NK Lymphocytes in Aging
  • 批准号:
    8384461
  • 项目类别:
  • 资助金额:
    $22.28万
  • 财政年份:
    2012
  • 负责人:
    Charles T. Lutz
  • 依托单位:
Natural Killer Subset Senescence and Clonality in Aging
  • 批准号:
    7286019
  • 项目类别:
  • 资助金额:
    $5.83万
  • 财政年份:
    2006
  • 负责人:
    Charles T. Lutz
  • 依托单位:
Natural Killer Subset Senescence and Clonality in Aging
  • 批准号:
    7143838
  • 项目类别:
  • 资助金额:
    $6.01万
  • 财政年份:
    2006
  • 负责人:
    Charles T. Lutz
  • 依托单位:
海外基金